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ABSTRACT
The prevalent c.903+469T>C mutation in MTRR
causes the cblE type of homocystinuria by strength-
ening an SRSF1 binding site in an ESE leading to
activation of a pseudoexon. We hypothesized that
other splicing regulatory elements (SREs) are also
critical for MTRR pseudoexon inclusion. We demon-
strate that the MTRR pseudoexon is on the verge of
being recognized and is therefore vulnerable to sev-
eral point mutations that disrupt a fine-tuned balance
between the different SREs. Normally, pseudoexon
inclusion is suppressed by a hnRNP A1 binding ex-
onic splicing silencer (ESS). When the c.903+469T>C
mutation is present two ESEs abrogate the activity of
the ESS and promote pseudoexon inclusion.
Blocking the 3′splice site or the ESEs by SSOs is
effective in restoring normal splicing of minigenes
and endogenous MTRR transcripts in patient cells.
By employing an SSO complementary to both ESEs,
we were able to rescue MTRR enzymatic activity in
patient cells to approximately 50% of that in controls.
We show that several point mutations, individu-
ally, can activate a pseudoexon, illustrating that this
mechanism can occur more frequently than previ-
ously expected. Moreover, we demonstrate that SSO
blocking of critical ESEs is a promising strategy to
treat the increasing number of activated pseudoex-
ons.
INTRODUCTION
Expression of protein coding genes in eukaryotes relies on
correct splicing of pre-mRNA transcripts. During this pro-
cess the spliceosome removes intronic sequences from the
initial transcripts and joins together the exons to produce
a mature mRNA. It is thus crucial for the cell to identify
and process exons with high fidelity. Splice site sequences
are the major splicing signals recognized by the spliceoso-
mal machinery but due to their degeneracy (1,2) they are
not by themselves sufficient for efficient recognition of ex-
ons, and in silico analysis shows that non-functional copies
of splice site sequences are highly abundant in intronic re-
gions (3). Therefore, other cis-acting splicing regulatory el-
ements (SRE) are necessary to direct the spliceosomal pro-
teins to the correct splice sites for efficient splicing. Exonic
splicing enhancers (ESE) and intronic splicing enhancers
(ISE) are sequences commonly bound by proteins of the
serine/arginine-rich (SR) family, which stimulate exon in-
clusion (4). Conversely, members from the heterogeneous
nuclear ribonucleoprotein (hnRNP) family bind to exonic
splicing silencers (ESS) and intronic splicing silencers (ISS)
to repress exon inclusion (5).
Aberrant splicing often causes human diseases and ac-
cording to theHumanGeneMutationDatabase (HGMDR©
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9.1%) of all reported mutations affect the splicing process.
Furthermore, an estimated 25% of the mutations presumed
to be missense and nonsense mutations are in fact splic-
ing mutations (6,7). The majority of the reported splicing
mutations alter the conserved splice sites at exon–intron
junctions. However, in a growing number of cases aberrant
splicing results frommutations in positive or negative SREs
(3,8–13).
Sequences resembling functional splice sites
(pseudosplice-sites) are highly frequent in introns but
are rarely used during splicing (3,14). It is believed that this
may be due to intrinsic defects in the sequences themselves
(14) and the enrichment of splicing silencer motifs (15).
When two matching pseudosplice-sites are located close
in an intron they define a pseudoexon. Activation of a
pseudoexon, so that it is spliced into an mRNA, disrupts
gene expression and will often cause disease. All genes
harbor pseudoexons, but the number of pseudoexons in
our genome is not known and has so far only been loosely
estimated based on computational approaches (15,16).
Pseudoexon activation has traditionally been regarded as a
rare disease mechanism, which requires multiple changes
(mutations) to occur (14), but in recent years it has become
clear that apparently benign single nucleotide variations
can be sufficient to activate pseudoexons and cause dis-
ease and the number of reported cases has been increasing
(3,17). In most of the reported cases, pseudoexon activation
results from single nucleotide changes creating new splice
sites or increasing the strength of existing suboptimal splice
sites. This is most likely due to the fact that changes involv-
ing the splice site sequences are easier to recognize since
the consensus motifs are well established. We have recently
reported that the most frequent mutation in the methionine
synthase reductase (MTRR) gene, a deep intronic mutation
(c.903+469T>C), creates an SRSF1 binding ESE, which
leads to pseudoexon inclusion and causes the cblE type
of homocystinuria (18). Similarly, other groups have also
reported in other genes (PCCA, GLA, FGB, CFTR, ATM,
Col4A5 and MFGE8) that single nucleotide changes in
introns located outside splice site sequences can cause
pseudoexon activation and human disease (19–25). These
and other studies convincingly show that an intronic single
nucleotide change by affecting splicing regulatory elements
outside of the splice sites is sufficient to activate a pseu-
doexon and cause disease. It can therefore be hypothesized
that pseudoexons, like constitutive exons, are regulated
by a finely tuned balance between positive and negative
splicing regulatory elements and any single nucleotide
substitution that changes this balance may lead to pseu-
doexon activation. Because intronic sequences are typically
not examined during routine diagnostic procedures it is
likely that the prevalence of pseudoexon activation may
thus be underestimated. Additionally, the pseudoexon
containing mRNA may be degraded by NMD (26) due
to premature termination codons (PTCs) resulting from
frame-shifts in the coding sequence. Therefore, it can be a
challenge to identify disease-associated mutations caused
by pseudoexon activation.
Complementation group cobalamin E (cblE) type of ho-
mocystinuria (cblE; MIM# 236270) is a rare autosomal
recessive disease caused by deficiency of methionine syn-
thase reductase (MTRR; EC 1.16.1.8) (27,28). Methion-
ine synthase (MTR; EC 2.1.1.13) is a cobalamin-dependent
enzyme, which remethylates homocysteine to methionine
in the remethylation pathway of the methionine cycle and
MTRR is required to maintain methylcobalamin (MeCbl)
in its reduced form.During its cycle, the cob(I)alamin cofac-
tor of MTR becomes oxidized to cob(II)alamine rendering
the enzyme inactive. The dual redox flavoprotein MTRR is
then necessary for the reductive activation ofMTR. Patients
with MTRR deficiency exhibit hyperhomocysteinemia, ho-
mocystinuria and often hypomethioninemia, and manifest
clinically with failure to thrive, developmental delay mega-
loblastic anemia and white matter abnormalities (28,29).
This severe disease is treated mostly by betaine adminis-
tration, which supports the remethylation of homocysteine.
The MTRR gene is composed of 15 exons and 15 disease
causing mutations located in different exons were reported
(29). The most frequent mutation is a T>C transition lo-
cated deep within intron 6 (c.903+469T>C, p.S301fsX315)
(28,29). We have previously shown that the c.903+469T>C
mutation creates an ESE bound by SRSF1, which facili-
tates the recognition of a weak 5´splice site, leading to pseu-
doexon inclusion (18).
In recent years, short oligonucleotides have been used
to correct splicing defects (30). Splice-shifting oligonu-
cleotides (SSOs) are designed to be complementary to a
specific sequence in the pre-mRNA, which regulates the
inclusion/skipping of the exon. Modulation of the splic-
ing outcome with SSOs is a promising therapeutic ap-
proach because it allows for the correction of disease-
causing mutations affecting splicing without the need for
gene-replacement (31). Mutations leading to pseudoexon
activation often create or strengthen pre-existing splicing
signals, such as pseudo-splice sites and SREs, which can be
targeted by SSOs to restore normal splicing (17). Targeting
the 3′ss or the 5′ss sterically hinders binding of U2AF and
U1snRNP, respectively, and may thus inhibit inclusion of
the pseudoexon.
In the present study we use splicing reporter minigenes to
investigate the pseudoexon activation mechanism in more
detail and in particular the role of an additional ESE and
an ESS flanking the previously described ESE created by
the c.903+469T>C mutation. To explore the possibility of
novel therapies for this type of splicing defects we subse-
quently investigated whether SSOs can correct missplicing
and restore enzyme activity in fibroblasts derived from a
patient homozygous for the MTRR pseudoexon activating
mutation.
MATERIALS AND METHODS
Minigenes
The MTRR minigene (beta-globin variant) has previously
been described (18). Mutations in the MTRR minigene
were introduced byGeneScript Inc. (GenScript, Piscataway,
NJ, USA). Wild-type and mutant double stranded DNA
oligonucleotides corresponding to 21 nt. of five different
pseudoexons were inserted into the alternatively spliced sec-
ond exon in the RHC-Glo splicing reporter minigene (32)
as previously described (33). All constructs were sequenced.
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Splicing analysis of minigenes
HEK293, HeLa or HepG2 cells were plated in 6-well
plates so that each well contained 3 × 105 cells. After
24 h of incubation the cells were transiently transfected
with 0.8 g of either the wild-type or the mutant ver-
sions of MTRR minigenes using using X-tremeGENE 9
DNA (Roche, Indianapolis, IN, USA). Total RNA was
extracted 48 h post-transfection using Isol-RNA Lysis
Reagent (AH Diagnostics, Aarhus, Denmark). The RNA
was treated with RQ1RNase-FreeDNase (Promega,Madi-
son, WI, USA) and ethanol precipitated afterward. Re-
verse transcription was performed using the High Ca-
pacity cDNA Reverse Transcription Kit (Life Technolo-
gies, Thermo Fisher Scientific Inc., Waltham, MA, USA).
Polymerase chain reaction (PCR) was performed with for-
ward T3 (5′-aattaaccctcactaaaggg-3′) and reverse T7 (5′-
taatacgactcactataggg-3′) plasmid specific primers. Quantifi-
cation of the PCR products was performed in a Fragment
Analyzer instrument (Advanced Analytical Technologies).
Transfection of HEK293 cells followed by SSO treatment
Approximately 3 × 105 HEK293 cells were plated in 6-well
plates. After 24 h the cells were transiently transfected with
0,8 g of minigene plasmid DNA. 24 h post-transfection
the cells were transfected with 20 nM of MTRR ESE-
SSO (5′-gcugaaucuccuccggccauucuu-3′), MTRR 5′SS-SSO
(5′-uuccuggcugaccuuaguggacagc-3′), MTRR 3′ss-SSO (5′-
ucccuaguccuucccugaaguggaa-3′) and a non-targeting SSO
using Lipofectamine RNAiMAX transfection reagent (Life
Technologies). The SSOs were 2′-OMe-substituted phos-
phorothioate RNA (DNA Technology, Aarhus, Denmark).
Total RNA was extracted and RT-PCR was performed as
described above.
Treatment of patient cells with SSOs
Reverse transfection was performed with 90 nM of each
SSO using Lipofectamine RNAiMAX transfection reagent
(Life Technologies). Patient and control fibroblast cells were
plated in parallel in 6-well plates at a concentration of 15
× 104 cells per well. After 48 h of incubation total RNA
was extracted and cDNA synthesis was performed using
Superscript VILO Master Mix (Invitrogen Co., Carlsbad,
CA, USA). RT-PCR amplicons were separated by gel elec-
trophoresis.
RNA affinity purification of nuclear proteins
The affinity purification of RNA binding proteins was
performed with 3′-biotin coupled RNA oligonucleotides
(DNA Technology, Aarhus, Denmark) as previously de-
scribed (33). The sequences of the RNA oligonucleotides
were: WT (5′-ACUAGGGAAGAAUGGCUGGAGGA
GA-BIO-3′), MUT (5′-ACUAGGGAAGAAUGGCCGG
AGGAGA-BIO-3′), TCGGGA (5′-ACUCGGGAAGAA
UGGCUGGAGGAGA-BIO-3′). For each purification 100
pmol of RNA oligonucleotide was coupled to 100 l
of streptavidin-coupled magnetic beads (Invitrogen Co.,
Carlsbad, CA, USA) and incubated with HeLa nuclear ex-
tract (Cilbiotech S.A., Belgium). After washing, bound pro-
teins were investigated by western blotting using a mono-
clonal mouse antibody toward SRSF1 (AK96) fromZymed
Laboratories (Invitrogen Co., Carlsbad, CA, USA) or a
monoclonal antibody toward hnRNP A1 (sc-10029) from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Fibroblasts
Primary fibroblasts were grown in Dulbecco’s Modified Ea-
gle’s Medium (DMEM+GlutaMaxTM, Life Technologies),
supplemented with 10% (v/v) foetal calf serum (Life Tech-
nologies) and antibiotic-antimycotic mixture (penicillin 10
000 IU/ml, streptomycin 10 000 g/ml, amphotericin B 25
g/ml, Life Technologies).
Transformed fibroblasts were obtained by transfecting
primary fibroblasts with pRNS1 plasmid containing SV40
DNA sequences (28). Fibroblast from the Czech patient ho-
mozygous for the c.903+469T>C mutation (patient 2) in
(28) were taken from the repository and used for the stud-
ies after obtaining informed written consent of the patient’s
legal guardians. The study was approved by the Ethics
Committee of the General University Hospital, Prague (No
1889/12 S-IV).
Treatment of fibroblasts with SSOs
Reverse transfection was performed with 90 nM of each
SSO using Lipofectamine transfection reagent (Life Tech-
nologies). Transformed patient and control fibroblast cells
were plated in parallel in 6-well plates at a concentration
of 15 × 104 cells per well. After 48 h of incubation total
RNA was extracted and cDNA synthesis was performed
using Superscript VILOMasterMix (Invitrogen Co., Carls-
bad, CA, USA). RT-PCR amplicons were separated by gel
electrophoresis.
Transfection of transformed fibroblasts by electropora-
tion was performed with 450 nM of each SSO using a Gene
Pulser II electroporator and 0.4 cm gene-pulser cuvettes
(Bio-Rad). Total RNAwas isolated from the cells 48 h after
electroporation for RT-PCR analysis as described above.
MTRR activity in fibroblasts after SSO transfection
MTRR activity was determined indirectly by metaboli-
cally labeling of fibroblasts with [57Co]cyanocobalamin and
measuring synthesis of MeCbl and AdoCbl, respectively
(34,35). Shortly, radioactively labeled medium was added
24 h after lipofection/electroporation and radioactively la-
beled cobalamins extracted after 3 days incubation fol-
lowed by HPLC separation and quantitation by gamma-
counting. Levels ofMeCbl andAdoCbl were expressed as%
of total radioactivity of all cobalamin derivates including
cyanocobalamin and hydroxocobalymin.
In silico predictions
Putative splicing regulatory elements were predicted us-
ing the ESEfinder 3.0 program (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) (36).
4630 Nucleic Acids Research, 2015, Vol. 43, No. 9
In silico analysis of RNA-seq data
Geuvadis BAM files containing read alignments were
downloaded and a MISO compatible annotation of the
MTRR pseudoexon was generated using an in-house Perl
script. MISO was run and the resulting estimates were fil-
tered so that only samples with at least one read supporting
the inclusion product were used to estimate the overall in-
clusion level.MISO estimates of pseudoexon inclusion were
used as input to the groupBy program from the BEDTools
toolkit (37) to estimate mean inclusion and standard devia-
tion, which were used to calculate the confidence interval.
RESULTS
MTRR pseudoexon inclusion depends on the balanced inter-
play between ESS and ESEs elements
We have previously shown that the c.903+469T>C muta-
tion in the MTRR gene strengthens a preexisting SRSF1-
binding motif and thus that pseudoexon activation is most
likely caused by creation of an ESE and not loss of an ESS
(18). In order to further examine the activity of this mo-
tif we inserted wild-type and mutant sequences from the
MTRR pseudoexon and other pseudoexons where muta-
tions outside the splice site sequences cause pseudoexon
activation (20,22–24) into the RHC-Glo splicing reporter
minigene (32) and transfected HEK293 cells (Figure 1).
Transcripts from the wild-type minigenes show no inclu-
sion of the alternatively spliced exon 2, whereas all the
mutant minigenes, except the one harboring the mutant
CFTR sequence, includes the test exon. This indicates that
for all the tested pseudoexon sequences, except CFTR, the
disease-causing mutation causes pseudoexon inclusion by
creating/strengthening an ESE which is able to drive exon
inclusion in another genomic context. This further confirms
that the c.903+469T>C mutation creates an ESE and it is
also consistent with the proposedmechanisms, namely ESE
creation, for the other tested pseudoexons. The observed
lack of reporter exon inclusion from the mutant CFTR se-
quence is consistent with the proposedmechanism of loss of
an hnRNP A2 binding ESS by the mutation (24) and sug-
gests that the mutant CFTR sequence does not have ESE
activity.
The level and activity of splicing regulatory factors, like
SRSF1, vary between cell types. Therefore, we determined
whetherMTRR pseudoexon activation also varies between
different cell-types. For this analysis we transiently trans-
fected wild-type and mutant MTRR-minigenes (18) into
HEK293, HeLa and HepG2 cells (Supplementary Figure
S1). RT-PCR analysis shows that pseudoexon inclusion
from themutant minigene is most efficient in HEK293 cells,
nearly no pseudoexon inclusion is observed in HeLa cells
and some pseudoexon inclusion from the mutant minigene
is observed in HepG2 cells. These results demonstrate that
activation of the mutant MTRR pseudoexon is influenced
by cell-type, which in turn suggests that the degree of mis-
splicing and local enzyme deficiency may vary between dif-
ferent tissues.
Because exon recognition is usually determined by a
finely tuned balance between positive and negative splic-
ing regulatory sequences, we hypothesized that additional
SREs may contribute to the regulation of MTRR pseu-
doexon splicing. Therefore we inspected the sequences
flanking the ESE created by the c.903+469T>C mutation.
A potential SRSF1 binding motif (CAGCCTG; Figure 2A)
similar to the SRSF1-binding ESE (CAGACTG) present in
ACADM exon 5 (33) is present 11 bp downstream from the
created ESE and a hnRNP A1 binding motif (38) recently
demonstrated to cause exon skipping and disease when it is
created by a mutation in the weak exon 2 in ETFDH (13),
is present 9 bp upstream (Figure 2A). To investigate the
potential role of these motifs in regulation of pseudoexon
inclusion, we designed a set of MTRR minigenes where
the ACADM-like motif is disrupted in a mutant MTRR
background (MUT-362T andMUT-361T) and the hnRNP
A1 motif is disrupted in the wild-type MTRR background
(WT-TCGGGA) (Figure 2A). Furthermore, we generated
the original ACADM ESE (WT-361A/365C) and its cor-
responding ESE-inactivating c.362C>T mutant version in
the wild-type MTRR minigene (WT-361A/362T/365C).
Disruption of the ACADM-like ESE by introducing the
c.362C>Tmutation or another ESE-inactivating mutation,
c.361A>T, causes decreased pseudoexon inclusion from the
minigenes with the activatingMTRR c.903+469Tmutation
(Figure 2B).
The native ACADM ESE (33) has an adenosine (A) at
position c.361, which matches the consensus SRSF1 bind-
ing motif (ESE finder score 3.5/3.0) rather than the cyto-
sine (C) (ESE finder score 2.5/2.6) present in the MTRR
pseudoexon. We speculated whether increasing the SRSF1
score and thus the ESE strength of the ACADM-like ESE
by changing this nucleotide in the MTRR wild-type con-
text would be sufficient to activate pseudoexon inclusion.
However, this results only in a very modest increase in pseu-
doexon inclusion, showing that in the MTRR context the
C>A change at the position equivalent to ACADM c.361
does not increase ESE strength significantly. On the other
hand, reconstitution of the full ACADM ESE motif includ-
ing c.365C in theMTRR wild-type context shows that this
is sufficient to activate pseudoexon inclusion significantly,
although this change is apparently located outside the core
SRSF1 motif (Figure 2B).
Taken together these data show that the ACADM-like
motif in the MTRR pseudoexon has ESE activity, and
that the high levels of MTRR pseudoexon inclusion may
be accomplished through the synergistic effect of the ex-
isting ACADM-like ESE and the ESE created by the
c.903+469T>C mutation. Moreover, strengthening of ei-
ther ESE is sufficient to activate pseudoexon inclusion.
Interestingly, also disruption of the hnRNP A1 motif in
a wild-type MTRR background results in a higher level of
pseudoexon activation than the c.903+469T>C mutation,
suggesting that inclusion of the pseudoexon is normally re-
pressed by this hnRNP A1 binding ESS motif and further
underscoring that mutations in different splicing regulatory
elements can activate the pseudoexon. Using RNA-affinity
purification we could directly demonstrate that hnRNPA1,
as expected, binds to the TAGGGA motif and that this
binding is dramatically reduced when the motif is mutated
to TCGGGA (Figure 2C). This supports the notion that the
increased pseudoexon inclusion from the TCGGGA mu-
tant minigene is due to reduced binding of hnRNPA1 to the
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Figure 1. RHC-Glo splicing reporter minigene assay. Upper panel: schematic representation of the RHC-Glo splicing reporter minigene and the sub-
cloned sequences. Lower panel: Agarose gel electrophoresis of RT-PCR minigene splicing products expressed in HEK293 cells. Inclusion or exclusion of
exon 2 is indicated on the right. The gel pictures are representative results from two experiments.
ESS motif. Preliminary data employing siRNA mediated
knock down of hnRNPA1 in HeLa cells corroborates this
notion and indicate that pseudoexon inclusion efficiency in-
creases by a factor of 2–3x (data not shown).
Our results clearly show that MTRR pseudoexon acti-
vation can result from mutations in several distinct splic-
ing regulatory elements. In line with this, we speculated
that also Single Nucleotide Polymorphisms (SNP) reported
in this part of MTRR could activate the pseudoexon
and thereby compromise normal MTRR splicing. Conse-
quently, we tested the most common SNPs, rs77578255 (mi-
nor allele frequency: A= 0.074) and rs187296284 (minor al-
lele frequency: G = 0.004) for their effect on MTRR pseu-
doexon inclusion. However, these variants did not change
the splicing pattern of the MTRR minigene and it is thus
not likely that they predispose to disease by increasing pseu-
doexon inclusion efficiency (Figure 2B).
The SSO complementary to the ESE is most effective in ab-
rogating theMTRR pseudoexon activation
We next hypothesized that aberrant inclusion of theMTRR
pseudoexon could be prevented by using SSOs to block
binding of splicing factors to the splicing regulatory se-
quences. We designed three different SSOs, either comple-
mentary to the 5′ss, the 3′ss, or overlapping both the ESEs.
Minigenes with either the wild-type or the c.903+469T>C
mutantMTRR pseudoexon, as well as wild-type constructs
with a disrupted hnRNP A1 ESS motif (WT-TCGGGA)
were transfected into HEK293 cells and treated with SSOs.
Treatment with the 3′ss-SSO which blocks the relatively
strong 3′ss and the ESE-SSO which blocks both ESEs re-
sults in almost complete splicing correction. In contrast, the
5′ss-SSO which blocks the weak 5′ss does not correct splic-
ing (Figure 3). The splicing correction efficiency is similar
for the c.903+469T>C mutant minigene and the ESS inac-
tivatedWT-TCGGGAminigene. These results indicate that
the ESE-SSO, which overlaps both ESEs is very effective in
modulating pseudoexon inclusion, consistent with the hy-
pothesis that the c.903+469T>C mutant creates a funda-
mental ESE and that theACADM-like ESE is a prerequisite
for pseudoexon activation.
We then examined if SSO treatment could also correct
splicing in MTRR patient cells, and found that the ESE-
SSO effectively induces pseudoexon skipping in patient fi-
broblasts, restoring correctly spliced MTRR mRNA levels
almost to those observed in control fibroblast cells (Fig-
ure 4). This is consistent with the results from ESE-SSO
splicing correction of the minigenes. This effect persists at
least until 96 h after treatment and can be achieved with
different SSO-doses and transfection procedures (Supple-
mentary Figures S2 and S3 and data not shown). Treatment
with the 3´ss-SSO is not as efficient and shows only par-
tial restoration of correct splicing in patient cells, and the
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Figure 2. The balanced interplay between an hnRNP A1 binding ESS and two SRSF1 binding ESEs dictateMTRR pseudoexon activation. (A) Schematic
representation of the sequences fromMTRR-minigenes used and the nucleotide changes introduced. A pictogram of hnRNPA1 positionweightmatrix (38)
is shown above the putative ESS and the invariant position 2 of this motif is underscored. A pictogram of the SRSF1 position weight matrix (36) is shown
above the previously described ESE1 (18) and the ACADM like ESE. Indicated positions 361, 362 and 365 are relative to the ACADM coding sequence.
Nucleotide positions that were changed are underscored. (B) Splicing minigene assay.MTRR-minigenes were transiently transfected into HEK293. After
RNA isolation the splicing products were analyzed by RT-PCR. The upper panel shows the average of pseudoexon inclusion from two measurements of
each duplicate. Error bars represent the range. Quantification of PCR products was performed using a Fragment Analyzer instrument. The lower panel
shows a sample agarose gel electrophoresis displaying pseudoexon inclusion levels in the different cell lines. The lower bands represent correctly spliced
exons, whereas the upper bands representMTRR pseudoexon inserted between minigene exons.  marks the pseudoexon. (C) Binding of hnRNPA1 and
SRSF1 proteins. Biotinylated RNA oligonucleotides were used in a pull-down experiment with HeLa nuclear extract followed by SDS PAGE and western
blot analysis using antibodies against SRSF1 and hnRNPA1. Blank indicates a control lane from pull down without RNA oligonucleotides. NE is nuclear
extract. The displayed blots are representative result from at least three pull-down experiments.
5′splice site targeting 5′ss-SSOdoes not prevent pseudoexon
inclusion in patient fibroblasts (Figure 4).
ESE-SSO treatment restores MTRR enzymatic activity in
patient cells
We have shown previously that inclusion of the pseudoexon
in the MTRR mRNA disrupts the reading frame and cre-
ates a premature termination codon, which may lead to
decreased mRNA levels due to nonsense-mediated decay
(NMD), and consequently results in very low amounts of
MTRR enzyme (28). In order to determine whether the ob-
served correction of splicing by ESE-SSO treatment (Fig-
ure 4) results in restoration of MTRR activity we mea-
sured methylcobolamine (MeCbl) synthesis in patient and
control fibroblasts after ESE-SSO treatment andmonitored
adenosylcobolamine (AdoCbl) synthesis as a control. For
this purpose, patient and control fibroblast cells were trans-
fected with ESE-SSO or the non-targeting control SSO by
lipofection or electroporation. The transfected cells were
then metabolically labeled with [57Co]cyanocobalamin and
the cobalamin coenzyme synthesis was determined (34).
Transfection of patient cells with the ESE-SSO using lipo-
fection resulted in a 3.3-fold increase of MeCbl synthesis
and increase ofMTRRactivity from 16% to 47% (Figure 5).
Similar results were obtained when cells were transfected by
electroporation (data not shown). Together, these data show
that it is possible to rescue MTRR function in patient cells
by increasing its activity to approximately 50% of that in
controls when the ESE-SSO is used to correctMTRR splic-
ing.
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Figure 3. SSO treatment in HEK293 cells transfected with wild-type, mutant and TCGGGA MTRR-minigenes. (A) Splicing minigene assay. MTRR-
minigenes were transiently transfected into HEK293. 24 h after the cells were transfected with SSOs targeting either the 5′ss, 3′ss or both ESEs. After RNA
isolation the splicing products were analyzed by RT-PCR. The upper panel shows a sample agarose gel electrophoresis displaying pseudoexon inclusion
levels. The lower bands represent correctly spliced exons, whereas the upper bands represent MTRR pseudoexon inclusion.  marks the pseudoexon.
(B) Quantification of pseudoexon inclusion. Error bars represent the range. Quantification of PCR products was performed using a Fragment Analyzer
instrument.
DISCUSSION
Pseudoexon activation was originally thought to be a rare
and rather exotic event, which in order to occur requires that
the function of more than one splicing regulatory element is
altered by mutations (14). Despite this, and despite the fact
that analysis of the complete intronic sequences is usually
not routine in most diagnostic settings, activation of pseu-
doexons by single intronic mutations is now frequently re-
ported as disease mechanism (3,17). Although pseudoexon
activation in the majority of reported cases is caused bymu-
tations which increase splice site strength, there are also sev-
eral examples, like the MTRR pseudoexon (18), where the
activating mutation is located outside the splice sites (19–
25). This shows that a group of pseudoexons only require
mutation of a single splicing regulatory element located out-
side the splice sites in order to be fully activated.
In the present study we first show that the point mu-
tations that cause this type of activation of the Col4A5-,
FGB- and PCCA-pseudoexons, as well as theMTRR pseu-
doexon, all create ESE elements, which are able to activate
splicing in a different genomic context like the RHC-Glo
splicing reporter minigene. Our results are consistent with
previous studies, which indicate that activation of the FGB
pseudoexon is caused by creation of an SRSF1 binding ESE
(24). They are also consistent with our own previous data
(18) showing that activation of the MTRR pseudoexon by
the c.903+469T>C mutation is due to creation of a strong
SRSF1 binding motif, which is identical to a fundamental
SRSF1 binding ESE in the RON gene (MST1R) (39,40).
These data point to ESE activation as a common mech-
anism for pseudoexon inclusion and they support the no-
tion that the splicing regulatory elements affected by pseu-
doexon activating mutations are not unique, but represent
general splicing regulatory elements.
On this basis, and because splicing regulation is usually
regulated by a finely tuned balance between several positive
and negative splicing regulatory elements, we hypothesized
that also other splicing regulatory elements than the ESE
created by the c.903+469T>C mutation are fundamental
in regulation ofMTRR pseudoexon splicing. Consequently,
mutations in several parts of this pseudoexon could poten-
tially lead to its inclusion.
Splicing of the MTRR pseudoexon is regulated by several
SRE motifs
By examining the pseudoexon sequence surrounding the
ESE created by the c.903+469T>C mutation, we identified
an ACADM-like ESE, which is fundamental for exon 5 in-
clusion in the ACADM gene (33) and a hnRNP A1 bind-
ing ESS motif (Figure 2), previously demonstrated to in-
hibit exon inclusion, when created by disease-causing point
mutations in ETFDH (13) or APC (41).
In ACADM exon 5 a c.362C>T point mutation dis-
rupts the SRSF1 binding ESE resulting in skipping of the
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Figure 4. SSO treatment restoresMTRR splicing in patient cells. (A) Fibroblasts from a patient harboring the c.903+469T>C mutation were transfected
with SSOs that target either the 5′ss, the 3′ss, both ESEs (ESE-SSO), or a non-targeting sequence (NT). Control fibroblasts were treated in parallel. RNA
was extracted after 48 h. A representative agarose gel electrophoresis of the RT-PCR products is shown. The lower bands represent correctly spliced exons,
whereas the upper bands representMTRR pseudoexon inclusion between exon 6 and exon 7.  marks the pseudoexon. (B) Quantification of pseudoexon
inclusion in patient fibroblasts following SSO treatment. Error bars represent the range. Quantification of PCR products was performed using a Fragment
Analyzer instrument.
Figure 5. SSO treatment partially restores enzymatic activity of methionine synthase reductase (MTRR). Fibroblasts from a patient homozygous for the
c.903+469T>Cmutation were transfected with an SSO that target both ESEs (ESE-SSO) or a non-targeting sequence (Ctr). Fibroblasts were then labeled
with [57Co]cyanocabalamine and MTRR activity was determined indirectly by measuring methylcobalamine (MeCbl) synthesis (expressed as% of total
labeled cobalamin derivatives). Adenosylcobalamine (AdoCbl) synthesis was measured as a control. The vertical lines represent the range of duplicate
determinations in a representative experiment.
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exon (33). Given the similarity between the ACADM ESE
(CAGACTGC) and the ACADM-like ESE motif found in
the MTRR pseudoexon (CAGCCTGA), we hypothesized
that this sequence could function as an ESE and contribute
to activation of the MTRR pseudoexon. Our data con-
firmed this hypothesis and clearly demonstrated that the
ACADM-like motif has ESE activity and that this activ-
ity could be disrupted in the MTRR mutant background
by introduction of the disease-causing ACADM c.362C>T
(33) or anACADM c.361C>Tmutation, which also inhibits
ACADM exon 5 splicing (unpublished data). This shows
that the presence of the ACADM-like ESE motif makes the
MTRR pseudoexon sensitive to activating mutations and
that activation by the c.903+469T>C mutation is depen-
dent on this pre-existing ACADM-like ESE.
We also changed the balance between positive and nega-
tive splicing regulatory elements in theMTRR pseudoexon
by disrupting the identified hnRNP A1 motif in the wild-
type background. This resulted in an even more dramatic
activation of the MTRR pseudoexon than caused by the
c.903+469T>C mutation, illustrating that mutations that
disrupt ESS sequences can also cause MTRR pseudoexon
inclusion and that this particular hnRNPA1 binding ESS
normally contributes to inhibit pseudoexon inclusion. This
is consistent with the idea that pseudoexons are not rec-
ognized by the spliceosome because they are enriched with
splicing silencer motifs (15).
The fact that both the stimulatory effect of ACADM like
SRSF1 binding ESE and the inhibitory effect of the hnRNP
A1 binding ESS motif previously found in the ETFDH and
APC genes have comparable effects in the MTRR pseu-
doexon further supports the notion that the splicing regula-
tory elements, which regulate pseudoexon splicing are gen-
eral and able to function in different genomic contexts.
Taken together, our data support a model where bind-
ing of hnRNP A1 to the TAGGGA high affinity ESS
in wild-type MTRR inhibits splicing, maybe because hn-
RNP A1 bound to the high affinity site initiates cooper-
ative spreading of hnRNPA1 to weaker sites in a 3′-to-5′
direction thereby directly blocking access to the 5′ splice
site and other splicing regulatory elements (42). Simulta-
neously binding of hnRNP A1 to the ESS inhibits bind-
ing of SRSF1 both to the very weak SRSF1 motif in ESE1
in the wild-type pseudoexon and to the ACADM-like ESE
motif. This may affect recognition of the weak 5′ss by U1
snRNP, since this may be dependent on SRSF1 binding
to the ESEs. This model contributes to explain how wild-
type pseudoexon recognition and splicing into the MTRR
mRNA is prevented. When the c.903+469T>C mutation is
present, it changes the weak SRSF1motif in ESE1 to a very
strong site, whichmay act synergistically with theACADM-
like SRSF1 ESE to recruit U1 snRNP to the weak 5′ss de-
spite binding of hnRNP A1 to the flanking ESS does not
seem to be affected. SRSF1 binding to the ESEs may also
antagonize the cooperative spreading of hnRNPA1 bind-
ing from the TAGGGA high affinity ESS (Figure 6). To-
gether this leads to pseudoexon activation and the abnor-
mal splicing of the MTRR transcript observed in patients.
This model is supported by the fact that hnRNP A1 is a
well-established antagonist of SRSF1 (43,44). Moreover,
we have recently observed a similar type of balanced in-
terplay between hnRNPA1 and SRSF1 in ETFDH exon 2,
where creation of the hnRNPA1 binding ESS is suggested
to cause exon skipping by abolishing binding to flanking
SRSF1 sites (13). Interestingly, inACADM exon 5 a balance
also exists between the SRSF1 binding ESE, and a flanking
hnRNPA1 binding ESS. Here a silent polymorphism in the
ESS can abolish hnRNPA1 binding and thereby alleviate
the need for the strong SRSF1 binding ESE to be present in
order to ensure exon 5 inclusion (33). Finally, in the RON
oncogene (MST1R), a strong SRSF1 binding ESE with a
sequence identical to the MTRR pseudoexon ESE created
by the c.903+469T>C mutation, is also antagonized by a
hnRNPA1 binding silencer (45).
Our data show that pseudoexon activation is a dynamic
process, where different mutations may cause different lev-
els of activation dependent on which splicing regulatory el-
ement they affect and what the effect on the functionality
of that element is.Moreover, by transfection of different cell
types we observed cell type specific differences in the level of
pseudoexon inclusion. Taken together these data suggested
to us that perhaps also the wild-type MTRR pseudoexon
has a minimal level of inclusion in normal cells, and per-
haps the degree of pseudoexon inclusion may vary between
individuals.
TheGeuvadis RNA sequencing project (46) hasmade the
RNA-seq data of 467 individuals publicly available, and we
used the splicing analysis programMISO (47) to quantitate
the level of pseudoexon inclusion in these samples. We iden-
tified detectable wild-type MTRR pseudoexon inclusion
(at least one read) in 140 individuals (30%), with a mean
estimated inclusion of 4% (Confidence interval (CI-95%)
= 3.6%–4.3%). This confirms that the wild-type MTRR
pseudoexon is indeed included at a minimal level in blood
cells from some individuals. Consequently, we extended our
analysis to include also theATM,CFTR,COL4A5, PCCA,
FGB, GLA as well as MCCC2 and MFGE8 pseudoexons
since these all have functional splice sites and can be acti-
vated by a single mutation to cause activation and disease,
suggesting that they may also be at the verge of activation
and that minor changes, such as genetic variation in splic-
ing regulatory elements or changes in the levels of splicing
factors may lead to inclusion. We observed low levels of in-
clusion of the PCCA pseudoexon located in intron 14 (22),
which was detected by at least 1 read in 14 samples, with a
mean estimated inclusion of 5.0% (CI-95% = 4.3%–5.7%).
The GLA pseudoexon located in intron 4 (19) was detected
by at least 1 read in 286 samples, with a mean estimated in-
clusion of 6.0% (CI-95% = 5.6%–6.4%). For the MCCC2
pseudoexon in intron 10 (48), we identified exon inclusion
(min 1 read) in 114 samples, with a mean estimated inclu-
sion of 4.5% (CI-95% = 3.5%–5.2%). The pseudoexon re-
ported in intron 6 of MFGE8 (25) was detected in 44 sam-
ples, with a mean estimated inclusion of as much as 14.9%
(CI-95% = 12.6%–17.3%). Manual inspection revealed sig-
nificant intron retention relative to theMFGE8 pseudoexon
inclusion level, likely affecting theMISO analysis. However,
in 40 samples we detected at least one splice junction read
between the pseudoexon and the neighboring exons, con-
firming inclusion of the pseudoexon. We could not detect
any inclusion of theATM,CFTR,COL4A5 and FGB pseu-
doexons (20–21,23–24) in the Geuvadis sample set, but this
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Figure 6. Splicing model of the MTRR pseudoexon activation induced by the c.903+469T>C mutation. The wild-type sequence harbors a very weak
SRSF1 binding ESE1, a flanking ACADM like SRSF1 binding ESE and a hnRNP A1 binding ESS. In the wild-typeMTRR gene binding of hnRNP A1
to the TAGGGA high affinity ESS inhibits splicing because this initiates cooperative spreading of hnRNPA1 to weaker sites in a 3′-to-5′ direction thereby
directly blocking access to the 5′ splice site and other splicing regulatory elements. Simultaneously binding of hnRNP A1 to the ESS inhibits binding of
SRSF1 both to the very weak SRSF1 motif in ESE1 and to the ACADM-like ESE motif. This also affects recognition of the weak 5′ss by U1 snRNP,
since this may be dependent on SRSF1 binding to the ESEs. When the c.903+469T>C mutation is present it changes the weak SRSF1 motif in ESE1 to
a very strong site, which may act synergistically with the ACADM-like SRSF1 ESE to recruit U1snRNP to the weak 5′ss despite binding of hnRNP A1
to the flanking ESS does not seem to be affected. SRSF1 binding to the ESEs also antagonizes the cooperative spreading of hnRNPA1 binding from the
TAGGGA high affinity ESS. Together this leads to pseudoexon activation and the abnormal splicing of theMTRR transcript observed in patients.
was not surprising since these genes are all expressed at low
levels in lymphocytes.
However, detection of low levels of the MTRR, GLA,
MFGE8,MCCC2 and PCCA pseudoexon inclusion in nor-
mal lymphocytes by RNA-seq illustrates that pseudoexon
inclusion is dynamic, and most importantly, that identifi-
cation of new pseudoexons using RNA-seq of normal cells
is possible. This approach could be used to identify pseu-
doexons, which are at risk of becoming active by single mu-
tational events or by SNPs. Such knowledge would be valu-
able for evaluation of disease associated sequence variations
located in introns in the future.
SSOs can efficiently correct splicing of the MTRR pseu-
doexon and increase enzyme activity
SSOs have been used successfully in recent years as a
therapeutic approach to correct splicing defects caused by
disease-causing mutations in numerous genes (22,24,49–
54).
In the present study we tested three different 2′-OMe
Phosphorothioate RNA SSOs, targeted to the 5′splice site,
the 3′splice site or a region harboring both ESEs, for
their ability to correct aberrant splicing caused by the
c.903+469T>C mutation. The SSOs targeted to the 3′ss
(3′ss-SSO) or the ESEs (ESE-SSO) significantly reduced
pseudoexon inclusion, while the SSO complementary to the
5′ss (5′ss-SSO) had no effect (Figure 4). These results could
simply be explained by limited binding of the 5′ss-SSO to
the weak 5′ splice site, due to limited access to the target
sequence during splicing or that the 5′ss-SSO itself forms a
secondary structure inhibiting its binding.
Alternatively, the lack of effect from the 5′ss-SSO could
be due to the fact that the 5′ss of theMTRR pseudoexon is
weak and that pseudoexon recognition primarily relies on
the ESEs and the strong 3′ss to initiate recruitment of the
spliceosomal components. Once spliceosome formation is
initiated recruitment of U1 snRNP displaces the 5′ss-SSO
at the 5′ss and the pseudoexon can be spliced. Conversely,
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when the 3′ss-SSO blocks the 3′ss or the ESE-SSO blocks
the ESE motifs, recruitment of the spliceosome is inhib-
ited. The 5′ss is too weak to initiate recruitment of spliceo-
somal components and the pseudoexon is instead skipped.
If this hypothesis is correct it might imply that SSOs tar-
geting the strongest splice site or a strong ESE would be
most efficient in inhibiting inclusion of activated pseudoex-
ons. Although no systematic testing of this hypothesis has
been performed it is supported by a recent study report-
ing SSO mediated inhibition of an activated pseudoexon in
the CAPN3 gene (54). In this case the disease causing mu-
tation activates the pseudoexon by increasing the strength
of a weak 3′splice site. However, recognition of the acti-
vated mutant pseudoexon is dependent on an SRSF1 bind-
ing ESE. Targeting the strengthened 3′splice site with an
SSO only resulted in partial pseudoexon skipping, whereas
targeting the strong 5′splice site or the SRSF1 ESE rescued
splicing almost completely. The efficiency of SSO mediated
ESE blocking to achieve skipping of activated pseudoex-
ons was also demonstrated for the FGB pseudoexon. Here
an SSO which targeted to the SRSF1 binding ESE created
by the disease-causing mutation in the FGB pseudoexon
also very efficiently inhibited pseudoexon inclusion from an
FGB splicing reporter minigene (24).
Interestingly, treatment with our ESE-SSO could also
normalize splicing from the MTRR TCGGGA minigene,
where pseudoexon activation is caused by loss of the hn-
RNPA1 binding ESS. First of all, this underscores that the
function of the ACADM-like ESE is critical for MTRR
pseudoexon activation, since the ESE-SSO blocking of this
ESE, in the absence of the hnRNP A1 binding ESS, is suffi-
cient to inactivate pseudoexon inclusion. Secondly, it illus-
trates that SSO blocking of a critical ESE is sufficient to
counteract pseudoexon activation caused by mutations af-
fecting other critical elements in the pseudoexon. This sug-
gests that optimizing an SSO-based therapy targeting only
one critical ESE in a pseudoexon could be used to antago-
nize the activating effect of several different activating mu-
tations located in other parts of the pseudoexon thereby al-
leviating the need for designing specific SSOs targeting each
new activating mutation. Moreover, the risk of undesired
splicing changes in other genes resulting from off-target ef-
fects of the SSO is limited when targeting exonic sequences
harboring ESEs, since such sequences, in contrast to splice
site sequences, are gene-specific.
Finally, we show that SSO therapy targeting the ESE is
able to correct abnormal splicing in patient cells harboring
the c.903+469T>Cmutation and that this increasesMTRR
enzymatic activity to levels which could be sufficient to ob-
tain therapeutic effect.
The present study shows that SSO blocking of ESEs
could be a promising strategy to treat the increasing num-
ber of activated pseudoexons, which are likely to be detected
as this phenomenon is receiving more attention and high
throughput sequencing techniques are adopted into clinical
settings.
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